Woodley Equipment Company to Attend ICSE Exhibition, Barcelona
September 26, 2016Clinical Trials Supplier, medical and laboratory equipment provider
Woodley Equipment is attending ICSE Exhibition taking place on 4th to 6th October 2016 at Fira de Barcelona Gran Via, Barcelona, Spain.
FDA gives the green light to the first Humira biosimilar
September 26, 2016Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira
Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …
NICE approval for restricted-use hypophosphatasia therapy
September 23, 2016Medical Communications, Sales and Marketing Alexion Pharmaceuticals, Strensiq, hypophosphatasia
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …
Top ten stories in the pharmaceutical industry this week
September 23, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and …
Alzheimer’s drug failure sends Lundbeck’s shares crashing
September 23, 2016Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings
Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …
Novo Nordisk to provide discounted insulin to poorest nations
September 23, 2016Medical Communications, Sales and Marketing Novo Nordisk, diabetes, insulin
Danish pharma firm Novo Nordisk has announced its intention to provide insulin at discounted prices to the world’s poorest nations …
Novartis’ Zykadia smashes Phase III target for lung cancer
September 23, 2016Medical Communications, Research and Development Novartis, lung cancer, zykadia
Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …
DNA damage response biotech launches with £25m funding
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dna damage response, funding
Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science …
193 countries sign UN declaration to fight drug-resistant infection
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jeremy Hunt, UN, drug-resistant infection
A historic UN declaration to fight drug-resistant infection across the globe has been signed by 193 countries at the United …
Gilead terminates Phase II/III study for ulcerative colitis antibody
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, ulcerative colitis
Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …
AZ withdraws European filing for ovarian cancer therapy
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer
AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …
EpiPen CEO appears before US lawmakers to defend “sickening” price hikes
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Heather Bresch, Mylan, epipen
Disgraced Mylan CEO Heather Bresch (pictured) has appeared before US lawmakers to defend the company’s now infamous and much-maligned inflation …
GSK appoints Emma Walmsley as first female CEO
September 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, appointment
GlaxoSmithKline, the UK’s biggest drugs company, has appointed Emma Walmsley as its new CEO. Walmsley will step into the vacancy …
GE Healthcare doubles India investment
September 21, 2016Manufacturing and Production, Research and Development, Sales and Marketing GE Healthcare, India
UK firm GE Healthcare is set to double its investment in India as it aims for revenues of £750 million …
Positive Phase III results for Amgen’s Repatha for coronary artery disease
September 21, 2016Research and Development Amgen, Phase III trial, Repatha
Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …
Teva and Regeneron team up for $2.6 billion pain treatment development
September 21, 2016Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis
Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …
AstraZeneca and Microsoft to develop ‘drag and drop’ cancer simulation
September 21, 2016Medical Communications, Research and Development AstraZeneca, Digital Pharma Guide, Microsoft
AstraZeneca has entered into a partnership with tech giant Microsoft to develop a new computerised modelling system which promises to …
Allergan expands NASH portfolio with $1.7 billion in acquisitions
September 21, 2016Research and Development, Sales and Marketing Akarna Therapeutics, Allergan, Tobira Therapeutics, acqusition, nash
Allergan has gone on a spending spree this week, snapping up clinical-stage biotech Tobira Therapeutics and privately-held Akarna Therapeutics for …
Sanofi reveals promising data for relapsing remitting MS treatment
September 20, 2016Manufacturing and Production, Research and Development RRMS, Sanofi, relapsing remitting multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi Genzyme, the speciality care global business unit of the French pharma firm announced six-year investigational data on Lemtrada (alemtuzumab) …
Bayer CEO defends $66 billion Monsanto acquisition
September 20, 2016Manufacturing and Production, Sales and Marketing Bayer, Werner Baumann, monsanto
Bayer AG’s chief executive Werner Baumann has spoken in defence of the company’s move last week to acquire US agricultural …
